(L-R) Dr Nagendra Hegde, associate director, Ella Foundation and Dr Krishna Ella, founder & director, Ella Foundation.
Genome Valley-based Ella Foundation on April 27, 2015 announced the completion of preliminary studies on an Ebola vaccine. The vaccine candidate is a human adenovirus engineered to contain an optimized synthetic gene based on viruses from the 2014 Ebola outbreak. Its platform uses controlled production of the glycoprotein.
The Ebola virus has a short ribbon-like structure, and contains a coat studded with a spike-like protein called the glycoprotein and immune responses against this protein can help protect against disease.
Founded and funded by Dr Krishna Ella and Ms Suchitra Ella, Ella Foundation is among the two foundations from the Asian region which had the unique distinction of winning the Gates Foundation Grand Challenges Explorations (GCE) grant, an initiative funded by the Bill & Melinda Gates to foster innovation in global health research.
Announcing the development Dr Krishna Ella, founder director of Ella Foundation said "we believe Innovation needs to be pursued and funneled into control strategies whenever appropriate. No nation can withstand sudden shocks, whether these come from a changing climate or a virus. Availability of a vaccine should help India in its preparedness to combat the disease in case the virus lands on our shores. It would also be useful to protect our healthcare and military aid workers to African nations and attain world-wide immunization goals."
This program is an important step from Ella Foundation to support World Immunisation Goals. Applauding the world immunisation week initiated by WHO and observed in the last week of April every year, Dr Ella pointed out Childhood immunisation is one of the most efficient ways to protect the health of children, family, and community. It is among the most cost-effective public health measures that helps minimize disease burden.